Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Gharaibeh, Mahdi
McBride, Ali
Bootman, J. Lyle
Cranmer, Lee D.
Abraham, Ivo
机构：
[1] Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6605
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian D.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [23] Chemotherapy in Pancreatic Cancer: Comparative Study of Gemcitabine, S-1, and FOLFIRINOX, Nab-Paclitaxel plus Gem
    Miyata, H.
    Yamago, H.
    Ueki, H.
    Nagamatsu, K.
    Iwasaki, R.
    PANCREAS, 2019, 48 (10) : 1492 - 1492
  • [24] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [26] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [27] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [28] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [29] A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc)
    Davelaar, John
    Tighiouart, Mourad
    Hendifar, Andrew Eugene
    Osipov, Arsen
    Moshayedi, Natalie
    Placencio-Hickok, Veronica
    Bhowmick, Neil
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
12345